



NAVIGATING URINARY TRACT INFECTIONS: ANTIBIOTIC RESISTANCE DYNAMICS AND TREATMENT PERSPECTIVES

Arun K S¹ Prejish C² Jomol P J³ Anakha Vijayan⁴ Bernaitis L⁵

¹Scientific officer, Metropolis Health care, Ernakulam, Kerala, India - 682025

²Assistant Professor, Department of microbiology, Al Jamia Arts and Science college, Malappuram Dt, Kerala, 679325

³Senior Executive – Quality Controller, ToxiVen Biotech Private Limited, Coimbatore, Tamil Nadu, 641042

⁴Post graduate, Department of Biotechnology, MG University, Kottayam, Kerala, 686560.

⁵Associate professor, Department of microbiology, Nandha siddha medical college, Erode, Tamilnadu – 638107.

Corresponding Author: Dr. Bernaitis L, Associate Professor, Department of Microbiology, Nandha Siddha Medical College and Hospital, Erode-638052.

ABSTRACT

One of the most common medical disorders, urinary tract infections (UTIs) affect the kidneys, ureters, bladder, and urethra. Most of these infections affect the bladder and urethra, which are the main organs in the lower urinary system. Depending on the site and symptoms of the infection, UTIs might present as acute pyelonephritis, cystitis, or urethritis. UTIs can arise as a result of multiple risk factors. *Escherichia coli*, *Klebsiella* species, *Enterococcus faecalis*, *Pseudomonas aeruginosa*, *Proteus* species, *Enterobacter* species, coagulase-negative *Staphylococci*, and *Acinetobacter* species are common bacteria that cause these illnesses. Through processes including transformation, conjugation, transduction, and cross-resistance, antibiotic resistance in bacteria that cause urinary tract infections is quickly rising. The potential of plant-based therapies as alternate UTI treatment alternatives is also explored in this paper.

KEYWORDS: Urinary tract infections, Antibiotic resistance, Uropathogens, Cystitis, Pyelonephritis, Alternative medicine

INTRODUCTION

Urinary tract infections (UTIs) are among the most common types of infections, typically caused by microorganisms affecting the kidneys, ureters, bladder, and urethra. Most UTIs occur in the lower urinary tract, primarily involving the bladder and urethra (1). Women are at a higher risk of developing UTIs compared to men. Symptoms of UTIs can include a burning sensation during urination, frequent urge to urinate with small amounts of urine, cloudy urine, urine that appears red, bright pink, or cola-colored indicating blood, strong-smelling urine, and pelvic pain in women (2).

UTIs can be categorized based on symptoms and the affected area. Acute pyelonephritis, for example, presents with back and side pain, high fever, nausea, and vomiting. Cystitis is characterized by pelvic pressure, lower abdominal discomfort, frequent painful urination, and blood in urine. Urethritis involves burning during urination and discharge. UTIs occur when bacteria enter the urinary tract through the urethra and multiply in the bladder (3). Although the urinary system has defense mechanisms to prevent infections, sometimes these defenses fail, leading to infection. The most common cause of bladder infection (cystitis) is *Escherichia coli*, part of the normal human flora. Infections of the urethra (urethritis) are usually caused by gastrointestinal bacteria (4).

RISK FACTORS IN UTIs

The microorganisms commonly causing UTIs include

Several bacterial species are commonly associated with urinary tract infections (UTIs), posing challenges to effective treatment and management. Among these are *Escherichia coli* (*E. coli*), which is the most prevalent pathogen responsible for UTIs, particularly in community-acquired cases. *Klebsiella* species, including *Klebsiella pneumoniae*, are also frequently implicated in UTIs, especially in healthcare settings. *Enterococcus faecalis*, a gram-positive bacterium, can cause UTIs, particularly in individuals with underlying health conditions. *Pseudomonas aeruginosa*, known for its multidrug resistance, is another significant pathogen associated with complicated UTIs (9). Additionally, various species of *Enterococcus*, *Proteus*, *Enterobacter*, coagulase-negative *Staphylococci*, and *Acinetobacter* are commonly isolated pathogens in UTIs, each presenting unique challenges in treatment and antibiotic resistance profiles. Understanding the diverse array of bacterial species involved in UTIs is crucial for implementing targeted therapeutic strategies and mitigating the impact of antibiotic resistance in clinical practice (10).



Antibiotic Resistance in UTI Pathogens

Antibiotic resistance in urinary tract infection (UTI) pathogens continues to pose significant challenges in clinical practice, necessitating ongoing research and surveillance efforts. Recent updates in this field highlight the evolving landscape of antibiotic resistance patterns among UTI-causing pathogens compared to earlier publications (11).

Escherichia coli (*E. coli*), the predominant cause of UTIs, has shown increasing resistance to commonly used antibiotics, such as trimethoprim/sulfamethoxazole, fluoroquinolones (e.g., ciprofloxacin), and cephalosporins. This trend is particularly concerning in community-acquired UTIs, where *E. coli* strains with extended-spectrum beta-lactamase (ESBL) production have become more prevalent, limiting treatment options and necessitating the use of carbapenems or alternative agents (12).

Klebsiella species, including *Klebsiella pneumoniae*, exhibit similar resistance trends, with rising rates of ESBL production and multidrug resistance, complicating UTI management in both community and healthcare settings (13). Additionally, carbapenem-resistant *Klebsiella* strains, often associated with healthcare-associated infections, pose significant therapeutic challenges due to limited treatment options and higher mortality rates.

Enterococcus faecalis, another common UTI pathogen, has shown variable resistance patterns, with some strains demonstrating resistance to ampicillin and vancomycin, further limiting treatment options in severe infections. *Pseudomonas aeruginosa*, known for its intrinsic and acquired resistance mechanisms, continues to exhibit multidrug resistance, particularly in complicated UTIs, necessitating the use of alternative agents such as polymyxins or aminoglycosides (14).

Other UTI pathogens, including *Proteus* species, *Enterobacter* species, coagulase-negative *Staphylococci*, and *Acinetobacter* species, have also demonstrated varying degrees of antibiotic resistance, posing challenges in empirical treatment selection and patient management (15).

Recent updates in antibiotic resistance patterns among UTI pathogens underscore the importance of antimicrobial stewardship, infection control measures, and the development of novel therapeutic strategies to address the growing threat of multidrug-resistant infections in clinical practice. Continual surveillance and research efforts are essential to monitor evolving resistance trends and inform evidence-based approaches to UTI management (16).

The Potential Alternatives for Antibiotics

Due to the challenges posed by microbial resistance, severe side effects, repeated high doses, high costs, and low efficacy of conventional antibiotics, researchers are increasingly motivated to explore natural remedies for the treatment of UTIs. Medicinal plants offer a wide range of therapeutic applications and are often used in communities lacking access to modern medical care (17). These traditional medicinal plants are employed to treat various ailments, including skin diseases, diabetes, UTIs, hepatitis, sexually transmitted diseases, cancer, hypertension, sexual impotence, and as contraceptives.

Herbal medicines are particularly effective against bacterial resistance due to their high efficacy and minimal or no side effects, along with easy availability. This has garnered significant attention from researchers interested in herbal treatments for UTIs. Some common medicinal plants used in managing and curing UTIs include *Vaccinium macrocarpon* (cranberry), *Tribulus terrestris*, *Trachyspermum copticum*, *Cinnamomum verum*, and *Hybanthus enneaspermus*. Although herbal medicines show great potential, further research is needed to explore their phytoconstituents and understand the mechanisms of action responsible for managing and curing UTIs (18).

Cranberry (*Vaccinium macrocarpon* Aiton) is the best-studied home remedy for UTIs. Evidence suggests that proanthocyanidins present in cranberries prevent bacteria from adhering to the walls of the urinary tract. Probiotics such as *Lactobacillus* and *Bifidobacterium* are beneficial microorganisms that act against infections in the urogenital tract (19). Reports on potential vaccine agents and antibodies targeting different toxins and effector proteins remain obscure, except for those targeting uropathogenic *E. coli*.

Other herbal remedies commonly explored for their potential antibacterial properties against UTIs include:

1. **Uva Ursi (*Arctostaphylos uva-ursi*):** This herb contains arbutin, which is metabolized in the body to produce hydroquinone, a compound with antimicrobial properties. Uva ursi has been traditionally used to treat urinary tract infections (20).
2. **Dandelion (*Taraxacum officinale*):** Dandelion has diuretic properties and may help increase urine production, potentially flushing out bacteria from the urinary tract (21).
3. **Goldenseal (*Hydrastis canadensis*):** Goldenseal contains berberine, a compound with antimicrobial properties that may help inhibit the growth of bacteria, including some strains of *E. coli* (22).



4. **Marshmallow Root (*Althaea officinalis*):** Marshmallow root has mucilage properties, forming a protective layer over the urinary tract lining and potentially reducing inflammation and irritation (23).
5. **Echinacea (*Echinacea purpurea*):** Echinacea is known for its immune-boosting properties and has been explored for its potential to support the immune system's response to bacterial infections (24).

While these herbal remedies show promise, it's essential to approach their use cautiously and consult with a healthcare professional, particularly for individuals with underlying health conditions or those taking medications (25). Additionally, more research is needed to establish the efficacy, safety, and optimal dosing of herbal remedies for UTI management. Integrating herbal remedies into comprehensive treatment approaches, alongside conventional medical therapies and preventive measures, may offer a multifaceted approach to combating UTIs while minimizing antibiotic use and mitigating the risk of resistance (26).

CONCLUSION

Urinary tract infections (UTIs) are among the most prevalent infections, particularly affecting women, and their treatment is increasingly challenged by the rising issue of antibiotic resistance. Misuse and overuse of antibiotics, along with genetic mutations in pathogens, have led to a significant increase in resistance, rendering many conventional treatments less effective and prompting longer and more intensive treatment regimens. These factors not only raise healthcare costs but also pose risks of side effects and further disruption of the human microbiome.

Preventive measures such as increased water intake, regular urination, avoiding irritants like alcohol and caffeine, and maintaining proper genital hygiene can help reduce the incidence of UTIs. However, given the growing problem of antibiotic resistance, there is an urgent need for alternative treatments.

Medicinal plants offer a promising solution, with a long history of use in traditional medicine for treating a wide range of ailments, including UTIs. Herbal remedies, such as those derived from cranberries and other medicinal plants, provide a natural, effective, and low-side-effect alternative to conventional antibiotics. Additionally, probiotics like *Lactobacillus* and *Bifidobacterium* show potential in preventing and managing UTIs.

Future research should focus on further exploring the phytoconstituents and mechanisms of action of these herbal remedies to fully understand their therapeutic potential. By integrating traditional knowledge with modern scientific research, we can develop more effective and sustainable treatments for UTIs, addressing the critical issue of antibiotic resistance and improving global health outcomes.

REFERENCE

1. Flores-Mireles A, Walker JN, Caparon M, Hultgren SJ. Urinary Tract Infections: Epidemiology, Mechanisms of Infection and Treatment Options. *Nat Rev Microbiol*. 2015;13(5):269–284. doi:10.1038/nrmicro3432.
2. Hill A. Medically reviewed by Kubala J. 8 Herbs and Natural Supplements for UTIs. *Healthline*. 2020 May 18.
3. Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH, et al. Antibiotic Resistance: A Rundown of a Global Crisis. *J Infect Drug Resist*. 2018;11:1645–1658. doi:10.2147/IDR.S173867.
4. Tan CW, Chlebicki MP. Urinary Tract Infections in Adults. *Singapore Med J*. 2016;57(9):485–490. doi:10.11622/smedj.2016153.
5. Shaheen G, Akram M, Jabeen F, Shah SMA, Munir N, Daniyal M, et al. Therapeutic Potential of Medicinal Plants for the Management of Urinary Tract Infection: A Systematic Review. *Clin Exp Pharmacol Physiol*. 2019;46(7):613–624. doi:10.1111/1440-1681.13124.
6. Patel H, Soni S, Bhagyalaxmi A, Patel N. Causative Agents of Urinary Tract Infections and their Antimicrobial Susceptibility Patterns at a Referral Centre in Western India: An Audit to Help Clinicians Prevent Antibiotic Misuse. *J Family Med Prim Care*. 2019;8(1):154. doi:10.4103/jfmpc.jfmpc_191_18.
7. Hooton TM, Scholes D, Hughes JP, Winter C, Roberts PL, Stapleton AE, et al. A Prospective Study of Risk Factors for Symptomatic Urinary Tract Infection in Young Women. *N Engl J Med*. 1996;335:468–474. doi:10.1056/NEJM199608153350703.
8. Lin HA, Yang YS, Wang JX, Lin HC, Lin DY, Chi CH, et al. Comparison of The Effectiveness and Antibiotic Cost among Ceftriaxone, Ertapenem, and Levofloxacin in Treatment of Community-acquired Complicated Urinary Tract Infections. *J Microbiol Immunol Infect*. 2016;49:237–242. doi:10.1016/j.jmii.2014.06.007.
9. Terlizzi M, Gribaudo G, Maffei M. Uropathogenic *Escherichia coli* (UPEC) Infections: Virulence Factors, Bladder Responses, Antibiotic, and Non-Antibiotic Antimicrobial Strategies. *Front Microbiol*. 2017;8:1566. doi:10.3389/fmicb.2017.01566.
10. Tessema NN, Ali MM, Zenebe MH. Bacterial Associated Urinary Tract Infection, Risk Factors, and Drug Susceptibility Profile among Adult People Living with HIV at Haswaassa University Comprehensive Specialized Hospital, Hawassa, Southern Ethiopia. *Sci Rep*. 2020;10:10790. doi:10.1038/s41598-020-67426-1.
11. Das S. Natural Therapeutics for Urinary Tract Infections – A Review. *Futur J Pharm Sci*. 2020;6(1):64. doi:10.1186/s43094-020-00076-z.



12. Gupta K, Trautner BW. Urinary Tract Infections, Pyelonephritis, and Prostatitis. In: Bennett JE, Dolin R, Blaser MJ, editors. *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*. 9th ed. Philadelphia: Elsevier; 2020. p. 882–909. doi:10.1016/B978-0-323-48246-4.00113-8.
13. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary Tract Infections: Epidemiology, Mechanisms of Infection and Treatment Options. *Nat Rev Microbiol*. 2015;13(5):269–284. doi:10.1038/nrmicro3432.
14. Medina M, Castillo-Pino E. An Introduction to the Epidemiology and Burden of Urinary Tract Infections. *Ther Adv Urol*. 2019;11:1756287219832172. doi:10.1177/1756287219832172.
15. Tandogdu Z, Wagenlehner FM. Global Epidemiology of Urinary Tract Infections. *Curr Opin Infect Dis*. 2016;29(1):73–79. doi:10.1097/QCO.0000000000000228.
16. Naber KG, Bergman B, Bishop MC, Bjerklund Johansen TE, Botto H, Lobel B, et al. EAU Guidelines for the Management of Urinary and Male Genital Tract Infections. *Eur Urol*. 2001;40(5):576–588. doi:10.1159/000047913.
17. Guo Y, Huang W, Wang L, et al. The traditional uses, phytochemistry, pharmacology, toxicology and quality control of *Cinnamomi Ramulus*: A review. *J Ethnopharmacol*. 2018;220:223–243. doi:10.1016/j.jep.2018.03.019.
18. Yap PSX, Yiap BC, Ping HC, Lim SHE. Essential oils, a new horizon in combating bacterial antibiotic resistance. *Open Microbiol J*. 2014;8:6–14. doi:10.2174/1874285801408010006.
19. Diop EA, Queiroz EF, Carvalho KM, et al. Evaluation of the anti-inflammatory, analgesic and antipyretic activities of the natural polyphenol chlorogenic acid. *Biol Pharm Bull*. 2002;25(12):1237–1240. doi:10.1248/bpb.25.1237.
20. Magalhães CB, Riva DR, DePaula LJ, et al. In vivo anti-inflammatory action of eugenol on lipopolysaccharide-induced lung injury. *J Appl Physiol* (1985). 2010;108(4):845–851. doi:10.1152/jappphysiol.01160.2009.
21. Kim M, Lim SJ, Kang SW, Um BH. In vitro antioxidant activity of some selected *Prunus* species in Korea. *Arch Pharm Res*. 2003;26(4):288–294. doi:10.1007/BF02980045.
22. Abubakar EM, Abboussi O, Mun'im A, Nindatu M, Halid A. Antimicrobial and antioxidant activities of endophytic fungi isolated from the leaves of *Cassia alata* Linn. *J King Saud Univ Sci*. 2015;27(4):334–341. doi:10.1016/j.jksus.2015.03.004.
23. Costa LC, da Silva TS, da Rocha RF, et al. Evaluation of analgesic and anti-inflammatory activities of the essential oil of *Lippia gracilis* leaves. *J Ethnopharmacol*. 2018;224:482–490. doi:10.1016/j.jep.2018.06.024.
24. Murugan K, Senthilkumar B, Senbagam D, et al. Novel synthesis of silver nanoparticles using leaf ethanol extract of *Cassia auriculata*: Characterization and their anti-bacterial activity. *Mater Lett*. 2013;105:220–223. doi:10.1016/j.matlet.2013.04.126.
25. Karimkhani MM, Ariff AB, Abdul Manan MA. *Cinnamomum cassia* bark in the production of quality vinegar: Optimizing the conditions using response surface methodology. *J Food Sci Technol*. 2015;52(4):2310–2318. doi:10.1007/s13197-014-1311-6.
26. Ibrahim MB, Ismail S, Omar W, Kassim JM, Bejo MH. In vitro antibacterial activity of *Melaleuca cajuputi* against clinical isolates of methicillin-resistant *Staphylococcus aureus*. *J Teknol*. 2013;65(3):49–52.